DelveInsight Evaluates a Robust Acute Pyelonephritis Pipeline as 10+ Influential Pharma Players to Set Foot in the Domain

March 15 19:09 2023
DelveInsight Evaluates a Robust Acute Pyelonephritis Pipeline as 10+ Influential Pharma Players to Set Foot in the Domain

DelveInsight’s, “Acute Pyelonephritis Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Acute Pyelonephritis Emerging drugs, the Acute Pyelonephritis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Pyelonephritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Acute Pyelonephritis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Acute Pyelonephritis clinical trials studies, Acute Pyelonephritis NDA approvals (if any), and product development activities comprising the technology, Acute Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Acute Pyelonephritis Pipeline Report

 

  • Over 10+ Acute Pyelonephritis companies are evaluating 10+ Acute Pyelonephritis pipeline therapies in various stages of development, and their anticipated acceptance in the Acute Pyelonephritis market would significantly increase market revenue.

 

  • The leading Acute Pyelonephritis Companies include VenatoRx Pharmaceuticals, Entasis Therapeutics, Paratek Pharmaceuticals, MerLion Pharmaceuticals, Spero Therapeutics, and others.

 

  • Promising Acute Pyelonephritis Pipeline Therapies includes Ceftazidime – Avibactam (CAZ-AVI), Doripenem, Omadacycline, Levofloxacin, TBPM-PI-HBr, Ertapenem, Dummy Infusion, Benapenem, Ertapenem, and others.

 

  • The Acute Pyelonephritis Companies and academics are working to assess challenges and seek opportunities that could influence in Acute Pyelonephritis R&D. The Acute Pyelonephritis pipeline therapies under development are focused on novel approaches to treat/improve in Acute Pyelonephritis.

 

Request a sample and discover the recent breakthroughs happening in the Acute Pyelonephritis Pipeline landscape @ Acute Pyelonephritis Pipeline Outlook Report

 

Acute Pyelonephritis Overview

Acute pyelonephritis is a bacterial infection causing inflammation of the kidneys. Pyelonephritis occurs as a complication of an ascending urinary tract infection that spreads from the bladder to the kidneys. Symptoms usually include fever, flank pain, nausea, vomiting, burning with urination, increased frequency, and urgency. The 2 most common symptoms are usually fever and flank pain. Acute pyelonephritis can be divided into uncomplicated and complicated.

 

Recent Developmental Activities in the Acute Pyelonephritis Treatment Landscape

 

  • In September 2020, tebipenem HBr completed a pivotal Phase III trial, ADAPT-PO, for the treatment of cUTI including acute pyelonephritis (AP).

 

  • Venatorx is currently enrolling a Phase III clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) including Acute Pyelonephritis. Venatorx believes that taniborbactam, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option.

 

For further information, refer to the detailed Acute Pyelonephritis Drugs Launch, Acute Pyelonephritis Developmental Activities, and Acute Pyelonephritis News, click here for Acute Pyelonephritis Ongoing Clinical Trial Analysis

 

Acute Pyelonephritis Emerging Drugs Profile Analysis

 

  • Tebipenem pivoxil: Spero Therapeutics

Spero’s lead product candidate, tebipenem HBr, is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infection and acute pyelonephritis. In September 2020, tebipenem HBr completed a pivotal Phase III trial, ADAPT-PO, for the treatment of cUTI including acute pyelonephritis (AP). If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and Acute Pyelonephritis.

 

  • Durlobactam: Entasis Therapeutics

Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, reported positive topline results from the company’s multi-national Phase 2 clinical trial of its β-lactamase inhibitor, ETX2514, in combination with sulbactam (the combination referred to as ETX2514SUL) in the treatment of complicated urinary tract infections acute pyelonephritis (kidney infection) in adults and complicated urinary tract infections. The results of the Phase 2 trial support progression of ETX2514SUL into Phase III, an important next step in developing pathogen-targeted products against drug-resistant bacterial infections.

 

  • VNRX-5133: VenatoRx Pharmaceuticals

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM enzymes. Venatorx believes that VNRX-5133, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option to meet unmet medical needs in patients with infections due to carbapenem-resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), suspected polymicrobial infections caused by both gram-negative and gram-positive susceptible pathogens, and engineerable bioterror pathogens such as Burkholderia spp. Venatorx is currently enrolling a Phase III clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) including Acute Pyelonephritis. Venatorx believes that taniborbactam, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option.

 

Acute Pyelonephritis Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Acute Pyelonephritis. The companies which have their Acute Pyelonephritis drug candidates in the most advanced stage, i.e. preregistration include, Spero Therapeutics.

 

Find out more about the Acute Pyelonephritis Pipeline Segmentation, Therapeutics Assessment, and Acute Pyelonephritis Emerging Drugs @ Acute Pyelonephritis Treatment Landscape

 

Scope of the Acute Pyelonephritis Pipeline Report

 

  • Coverage- Global

 

  • Acute Pyelonephritis Companies- VenatoRx Pharmaceuticals, Entasis Therapeutics, Paratek Pharmaceuticals, MerLion Pharmaceuticals, Spero Therapeutics, and others.

 

  • Acute Pyelonephritis Pipeline Therapies- Ceftazidime – Avibactam (CAZ-AVI), Doripenem, Omadacycline, Levofloxacin, TBPM-PI-HBr, Ertapenem, Dummy Infusion, Benapenem, Ertapenem, and others.

 

  • Acute Pyelonephritis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Acute Pyelonephritis Pipeline Companies and Therapies, click here @ Acute Pyelonephritis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Pyelonephritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute Pyelonephritis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Tebipenem pivoxil: Spero Therapeutics
  9. Drug profiles in the detailed report…..
  10. Late Stage Products (Phase III)
  11. VNRX-5133: VenatoRx Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. Durlobactam/sulbactam: Entasis Therapeutics
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Acute Pyelonephritis  Key Companies
  24. Acute Pyelonephritis  Key Products
  25. Acute Pyelonephritis – Unmet Needs
  26. Acute Pyelonephritis – Market Drivers and Barriers
  27. Acute Pyelonephritis – Future Perspectives and Conclusion
  28. Acute Pyelonephritis  Analyst Views
  29. Acute Pyelonephritis  Key Companies
  30. Appendix

 

Got Queries? Find out the related information on Acute Pyelonephritis Mergers and acquisitions, Acute Pyelonephritis Licensing Activities @ Acute Pyelonephritis Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author